This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
Ablynx, a pioneer in the discovery and development of Nanobodies(R), a novel class of antibody-derived therapeutic proteins, today announced that it has advanced ALX-0061, a new Nanobody(R)-based therapeutic programme, into preclinical development for the treatment of autoimmune and inflammatory diseases.
We care about your feedback. Let us know how we can improve your CancerCompass experience.